Benitec Biopharma Inc. (BNTC) Return on equity 2019–2024
Benitec Biopharma Inc. (BNTC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-46.0%FY2024 · since FY2019: 15.7% → -46.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -46.0% | +9638.1 pp |
| FY2023 | -9684.2% | -9052.4 pp |
| FY2022 | -631.8% | -562.4 pp |
| FY2021 | -69.4% | +11.4 pp |
| FY2020 | -80.8% | -96.5 pp |
| FY2019 | 15.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice